Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine in Frail Patients with Metastatic Breast Cancer
NCT00005614Phase 2Withdrawn
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 1999
- Primary completion
- Jun 2000
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in breast cancer, sponsored by Moffitt Cancer Center. Primary endpoint: Objective Response Rate at 2 years. Planned start Aug 1999; status: withdrawn.
02
Drugs
gemcitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00005614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005614.